REGULATORY

• Chuikyo Urges Rethink of Health Coverage for Conditionally Approved Regenerative Medicines
  August 9, 2024

• Pharma Opposes Off-Year Revision, but Payer Pushes Implementation as Premise
  August 8, 2024

• Chuikyo Disappointed over Industry Survey on 2024 Drug Pricing Reform
  August 8, 2024

• Novartis’ Fabhalta, UCB’s Briviact and More to Join NHI Price List on Aug. 15
  August 8, 2024

• Dupixent Braces for Third Re-Pricing, LEO/Lilly Meds Face Spillover Cuts
  August 8, 2024

• AstraZeneca’s Tezspire to Face 4.1% CEA Price Cut in November
  August 8, 2024

• MHLW to Issue Guidance for Setting Acceptable Limit for Nitrosamines This Fall
  August 6, 2024

• MHLW to Streamline Deliberations on JP Revisions to Facilitate Use of Overseas APIs
  August 6, 2024

• Humira Gets Health Coverage for nr-axSpA
  August 6, 2024

• Takeda’s Fruzaqla in Line for Approval, Broader Labels for Truvada, Keytruda, Prevenar 20 Too
  August 5, 2024

• Off-Year Debate Would Explore Ways to Address Drug Loss, Supply Issues with Drug Prices: Vice Minister
  August 2, 2024

• Lilly’s Alzheimer’s Med Donanemab Now in Line for Japan Approval
  August 2, 2024

• Nitrosamine Self-Inspection Deadline Extended to Aug. 1 amid Challenges
  August 1, 2024

• Prevenar 20 to Join National Immunization for Children from October
  August 1, 2024

• Japan Aspires to Double Private Investments in Pharma Startups over 5 Years
  July 31, 2024

• Japan OKs FY2025 Budget Ceiling, 410 Billion Yen for Social Security Cost Rise
  July 31, 2024

• MHLW Council Begins Discussions on Rx-to-OTC Switch of 3 New APIs
  July 31, 2024

• MHLW Panel Discusses Ways to Rationalize Ethical Narcotics Distribution
  July 30, 2024

• Japan Panel Backs Rx-to-OTC Switch of 4 PPIs
  July 30, 2024

• MHLW Mulls System to Seek Expert Input for Patent Linkage
  July 29, 2024

ページ

• « 先頭
• ‹ Prev
• …
• 42
• 43
• 44
• 45
• 46
• 47
• 48
• 49
• 50
• …
• Next ›
• 最終 »